AveXis
Biotech company is focused on developing gene therapy for patients with rare and life-threatening neurological genetic diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€236—355m (Dealroom.co estimates Sep 2015.)
Dallas Texas (HQ)
Financials
Estimates*
EUR | 2015 | 2016 | 2017 |
---|---|---|---|
R&D budget | 25.0m | 56.0m | 125m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Series A | |
N/A | N/A | Series B | |
$10.0m | Series C | ||
$65.0m | Series D | ||
N/A | N/A | IPO | |
N/A | N/A | Acquisition | |
$100k | Grant | ||
Total Funding | €68.3m |
Recent News about AveXis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.